EUROLIVE: Olive Polyphenols Raise HDL -- The Foundational Trial

EUROLIVE was a randomized crossover trial in 200 healthy European men, published in Annals of Internal Medicine in 2006, that tested three olive oils with low, medium, and high polyphenol content against one another. HDL cholesterol rose and markers of lipid oxidation fell in proportion to the polyphenol dose -- providing the controlled human evidence that anchors the 2011 EFSA health claim on olive oil polyphenols and protection of blood lipids from oxidative damage.

Why This Study Matters

EUROLIVE is the trial that established, in controlled human experimentation, that olive oil's cardiovascular effect is not solely a function of its monounsaturated fat. Refined olive oil contains nearly the same fatty-acid profile as extra virgin olive oil, but almost none of the phenolic compounds. If the only thing that mattered cardiovascularly was monounsaturated fat, the three oils in EUROLIVE should have produced equivalent results. They did not.

The trial was designed specifically to settle that question. Six research centers across five European countries (Spain, Denmark, Finland, Italy, and Germany) coordinated a crossover protocol in which the same 200 men cycled through all three oils, each for three weeks, separated by two-week washout periods. This is a more demanding design than a parallel-group trial -- it controls for between-subject variation by making each participant their own control. According to PubMed, the paper was published in Annals of Internal Medicine on September 5, 2006 (DOI: 10.7326/0003-4819-145-5-200609050-00006).

The findings were a dose-response curve: HDL cholesterol increased linearly with the polyphenol content of the olive oil, and markers of oxidative damage to LDL decreased linearly. That dose-response signal is the kind of evidence regulators look for when evaluating a health claim, because it suggests biological causation rather than confounding.

How It Was Designed

The basics are in the study design bar above: 200 healthy adult men, three-arm randomized crossover, six European research centers, three-week intervention periods.

The three olive oils were carefully matched on every variable except phenolic content. Low-polyphenol oil contained 2.7 mg/kg of phenolic compounds. Medium-polyphenol oil contained 164 mg/kg. High-polyphenol oil contained 366 mg/kg. Fatty acid composition, tocopherol content, and other minor components were equivalent across the three oils. The only meaningful difference between the interventions was the polyphenol load. This is the design that allows the trial to attribute observed differences specifically to phenolic content rather than to anything else in the oil.

Each participant consumed 25 mL per day of the assigned oil -- approximately 2 tablespoons -- for three weeks, then crossed over to a different oil after a two-week washout. The order of oil assignment was randomized. The trial measured plasma lipids, oxidative stress markers, and exogenous and endogenous antioxidant levels at baseline and at the end of each three-week intervention period.

The crossover design is methodologically important. Each man's HDL response on low-polyphenol oil was directly compared to his own HDL response on high-polyphenol oil. This removes the between-subject variability that would otherwise demand a much larger sample size. With 200 men and three crossover periods, the trial generated 600 person-interventions worth of data, comparable in statistical power to a parallel trial with several thousand participants.

What They Found

HDL cholesterol, the total-cholesterol-to-HDL ratio, and markers of LDL oxidation all moved in dose-response patterns with phenolic content:

Biomarker	Low-Phenol Oil	Medium-Phenol Oil	High-Phenol Oil	What It Measures
HDL change	+0.025 mmol/L	+0.032 mmol/L	+0.045 mmol/L	"Good" cholesterol
oxLDL change	+1.21 U/L	-1.48 U/L	-3.21 U/L	Oxidized LDL (plaque driver)
Total-C / HDL	Smallest reduction	Intermediate	Largest reduction	Atherogenic ratio
Triglycerides	-0.05 mmol/L	-0.05 mmol/L	-0.05 mmol/L	Blood fat (equal across arms)

Green indicates a favorable direction. The HDL increase and the oxidized LDL decrease both showed statistically significant linear dose-response with phenolic content (P for trend significant).

The 95% confidence intervals for HDL change excluded zero for all three oils, with the high-polyphenol oil producing the largest effect (mean change 0.045 mmol/L, CI 0.02 to 0.06). The oxidized LDL reductions were significant for the medium and high oils, with the high-polyphenol oil reaching -3.21 U/L (CI -5.1 to -0.8).

Reading the Results

The HDL signal. HDL cholesterol is part of the canonical lipid panel. Its relationship to cardiovascular risk is well-established, though more recent literature has nuanced the simple "higher HDL is better" framing in favor of HDL functionality measures. The EUROLIVE finding -- that polyphenol content drove HDL changes independent of fatty acid composition -- pointed to a previously underappreciated mechanism by which olive oil consumption shifts the lipid profile favorably. The effect size per intervention period was modest (a few percent), but it was reproducible across all six European centers and showed a clean dose-response.

The oxidized LDL signal. Oxidized LDL is the specific form of cholesterol that drives atherosclerotic plaque formation. It is more directly tied to cardiovascular events than total LDL alone. The fact that olive oil polyphenols, in a controlled crossover, reduced circulating oxidized LDL is the mechanism that connects EUROLIVE to the downstream hard-endpoint findings in PREDIMED and CORDIOPREV. The dose-response curve was particularly clean: at 2.7 mg/kg of phenolic content, oxidized LDL actually rose slightly; at 366 mg/kg, it fell substantially. The implication is that the phenolic concentration in the oil matters -- not just the volume consumed.

What this contributes mechanistically. Before EUROLIVE, the case for olive oil's cardiovascular effect rested primarily on the monounsaturated-fat hypothesis -- replace saturated fat with MUFA, improve the lipid panel. EUROLIVE established that this was incomplete. A measurable share of olive oil's effect on cardiovascular biomarkers tracks with phenolic content specifically. That mechanistic insight became the regulatory basis for the EFSA health claim five years later.

What Didn't Change

Glucose levels did not differ across the three oils in a clinically meaningful way. Triglyceride reductions were equivalent across the low, medium, and high polyphenol oils -- meaning triglyceride lowering appeared to be driven by the monounsaturated fat content rather than the phenolic content. Total LDL cholesterol changes were small and not dose-responsive with phenolic content. The polyphenol-specific effect appears concentrated on HDL and on lipid oxidation, not on broader glycemic or lipid measures.

The trial was conducted in 200 healthy male volunteers. Generalizability to women, to populations with diagnosed cardiovascular disease, and to non-European participants requires further evidence. The three-week intervention periods are also short relative to long-term cardiovascular outcomes; EUROLIVE establishes the biomarker mechanism, but the hard-endpoint evidence comes from PREDIMED and CORDIOPREV.

Broader Context

EUROLIVE is the foundational study behind the 2011 European Food Safety Authority opinion (Regulation 432/2012), which authorized a health claim for olive oil polyphenols and protection of blood lipids from oxidative damage at a daily intake of 5 mg of hydroxytyrosol and its derivatives. The EFSA panel specifically cited EUROLIVE in its mechanistic assessment. That makes EUROLIVE one of the few nutrition trials to have produced a regulator-authorized food health claim in the European Union.

The downstream literature builds directly on EUROLIVE's mechanism. PREDIMED (2018 republished, NEJM) showed 31% reduction in major cardiovascular events with a Mediterranean diet supplemented with extra virgin olive oil. CORDIOPREV (2022, The Lancet) extended that finding to secondary prevention in 1,002 patients with established coronary heart disease. The Harvard cohort studies (Guasch-Ferre 2020 and 2022, JACC) replicated the cardiovascular signal in U.S. populations. A 2018-2019 meta-analysis of 26 RCTs (Cicero / George et al., Crit Rev Food Sci Nutr) pooled the biomarker evidence and confirmed the high-polyphenol-versus-low-polyphenol effect on oxidized LDL, total cholesterol, and HDL.

EUROLIVE sits at the mechanistic foundation of that entire stack. It is the controlled experiment that linked phenolic content to lipid biology, and from there the literature traces outward to clinical outcomes.

Related Research

Continue exploring olive oil and polyphenol science:

• Hydroxytyrosol Improves 7 Biomarkers of Aging and Inflammation
• Olive Oil Phenolics Reduced Postprandial LDL Oxidation in Humans
• Olive Oils High in Phenolics Modulate Oxidative Status in Men

Source: View the original study on PubMed

Olivea's Dosage

EUROLIVE used 25 mL/day (approximately 2 tablespoons) of olive oil. The high-phenolic oil in the trial contained 366 mg/kg of polyphenols, which delivered roughly 9 mg of polyphenols per day -- above the EFSA threshold of 5 mg/day of hydroxytyrosol and derivatives required for the authorized health claim. A single tablespoon of Olivea extra virgin olive oil delivers approximately 14 grams. For a concentrated polyphenol dose, each Olivea capsule delivers over 20 mg of hydroxytyrosol per serving -- more than four times the EFSA daily threshold from a single capsule. Our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.